Short Bowel Syndrome Market (Product: Glucagon-like Peptide-2 [GLP2], Growth Hormone, Glutamine, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Sales)- Global Industry Analysis, Share, Growth, Regional Outlook And Forecasts, 2021-2027

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Short Bowel Syndrome Market, By Product

7.1.  Short Bowel Syndrome Market, by Product, 2021-2027

7.1.1.     Glucagon-like Peptide-2 (GLP2)

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Growth Hormone

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Glutamine

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     Others

7.1.4.1.          Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Short Bowel Syndrome Market, By Distribution Channel

8.1.  Short Bowel Syndrome Market, by Distribution Channel, 2021-2027

8.1.1.     Hospital Pharmacies

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Retail Pharmacies

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Online Sales

8.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Short Bowel Syndrome Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.     Market Revenue and Forecast, by Product (2016-2027)

9.1.2.     Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.1.3.     U.S.

9.1.3.1.          Market Revenue and Forecast, by Product (2016-2027)

9.1.3.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.1.4.     Rest of North America

9.1.4.1.          Market Revenue and Forecast, by Product (2016-2027)

9.1.4.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.2.  Europe

9.2.1.     Market Revenue and Forecast, by Product (2016-2027)

9.2.2.     Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.2.3.     UK

9.2.3.1.          Market Revenue and Forecast, by Product (2016-2027)

9.2.3.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.2.4.     Germany

9.2.4.1.          Market Revenue and Forecast, by Product (2016-2027)

9.2.4.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.2.5.     France

9.2.5.1.          Market Revenue and Forecast, by Product (2016-2027)

9.2.5.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.2.6.     Rest of Europe

9.2.6.1.          Market Revenue and Forecast, by Product (2016-2027)

9.2.6.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.3.  APAC

9.3.1.     Market Revenue and Forecast, by Product (2016-2027)

9.3.2.     Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.3.3.     India

9.3.3.1.          Market Revenue and Forecast, by Product (2016-2027)

9.3.3.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.3.4.     China

9.3.4.1.          Market Revenue and Forecast, by Product (2016-2027)

9.3.4.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.3.5.     Japan

9.3.5.1.          Market Revenue and Forecast, by Product (2016-2027)

9.3.5.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.3.6.     Rest of APAC

9.3.6.1.          Market Revenue and Forecast, by Product (2016-2027)

9.3.6.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.4.  MEA

9.4.1.     Market Revenue and Forecast, by Product (2016-2027)

9.4.2.     Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.4.3.     GCC

9.4.3.1.          Market Revenue and Forecast, by Product (2016-2027)

9.4.3.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.4.4.     North Africa

9.4.4.1.          Market Revenue and Forecast, by Product (2016-2027)

9.4.4.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.4.5.     South Africa

9.4.5.1.          Market Revenue and Forecast, by Product (2016-2027)

9.4.5.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.4.6.     Rest of MEA

9.4.6.1.          Market Revenue and Forecast, by Product (2016-2027)

9.4.6.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.5.  Latin America

9.5.1.     Market Revenue and Forecast, by Product (2016-2027)

9.5.2.     Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.5.3.     Brazil

9.5.3.1.          Market Revenue and Forecast, by Product (2016-2027)

9.5.3.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

9.5.4.     Rest of LATAM

9.5.4.1.          Market Revenue and Forecast, by Product (2016-2027)

9.5.4.2.          Market Revenue and Forecast, by Distribution Channel (2016-2027)

Chapter 10.   Company Profiles

10.1.                 Takeda Pharmaceutical Company Limited

10.1.1.  Company Overview

10.1.2.  Product Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.                 Merck KGaA

10.2.1.  Company Overview

10.2.2.  Product Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.                 Zealand Pharma A/S

10.3.1.  Company Overview

10.3.2.  Product Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.                 OxThera

10.4.1.  Company Overview

10.4.2.  Product Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.                 VectivBio AG

10.5.1.  Company Overview

10.5.2.  Product Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.                 9 Meters Biopharma, Inc.

10.6.1.  Company Overview

10.6.2.  Product Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.                 Nutrinia Ltd.

10.7.1.  Company Overview

10.7.2.  Product Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.                 Hanmi Pharm.Co., Ltd.

10.8.1.  Company Overview

10.8.2.  Product Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.                 Hanmi Pharm.Co., Ltd.

10.9.1.  Company Overview

10.9.2.  Product Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

Chapter 11.   Research Methodology

11.1.                 Primary Research

11.2.                 Secondary Research

11.3.                 Assumptions

Chapter 12.   Appendix

12.1.                 About Us

12.2.                 Glossary of Terms